Literature DB >> 1985197

Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain.

E O Freed1, D J Myers, R Risser.   

Abstract

The V3 loop, located near the middle of the surface envelope glycoprotein gp120, is the major neutralizing domain of human immunodeficiency virus type 1 (HIV-1). Although the majority of the V3 loop is highly variable between different strains of HIV-1, a Gly-Pro-Gly-Arg motif at the tip of the loop is highly conserved. To determine whether this region plays a role in fusion mediated by the HIV-1 envelope glycoproteins, we introduced seven single-amino-acid changes in the V3 loop. The mutant envelope glycoproteins were expressed from an HIV-1 envelope expression vector and analyzed for their ability to induce cell fusion in the absence of virus replication. Our results indicated that single-amino-acid changes in the V3 loop were capable of completely abolishing or greatly reducing the ability of the HIV-1 envelope glycoproteins to induce cell fusion, thereby identifying the V3 loop as a fusion domain of HIV-1. Mutations in the highly conserved tip of the loop or in a nonconserved region flanking the highly conserved tip had no effect on envelope glycoprotein synthesis, processing, transport, or binding to the CD4 receptor molecule. Mutation of the putative disulfide bridge-forming Cys at residue 336 blocked gp160 cleavage and CD4 binding.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985197      PMCID: PMC240504     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

2.  A chink in HIV's armour?

Authors:  P E Stephens; G Clements; G T Yarranton; J Moore
Journal:  Nature       Date:  1990-01-18       Impact factor: 49.962

3.  Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.

Authors:  E O Freed; D J Myers; R Risser
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

4.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity.

Authors:  J Sodroski; W C Goh; C Rosen; K Campbell; W A Haseltine
Journal:  Nature       Date:  1986 Jul 31-Aug 6       Impact factor: 49.962

6.  Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants.

Authors:  E Helseth; M Kowalski; D Gabuzda; U Olshevsky; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

7.  Characterization of HIV-1 neutralization escape mutants.

Authors:  J A McKeating; J Gow; J Goudsmit; L H Pearl; C Mulder; R A Weiss
Journal:  AIDS       Date:  1989-12       Impact factor: 4.177

8.  Functional contribution of cysteine residues to the human immunodeficiency virus type 1 envelope.

Authors:  E Tschachler; H Buchow; R C Gallo; M S Reitz
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

9.  Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain.

Authors:  Y Devash; T A Calvelli; D G Wood; K J Reagan; A Rubinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

10.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Javaherian; A J Langlois; C McDanal; K L Ross; L I Eckler; C L Jellis; A T Profy; J R Rusche; D P Bolognesi; S D Putney
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

View more
  93 in total

1.  Neutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count.

Authors:  M Nokta; P Turk; K Loesch; R B Pollard
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

2.  Research on anti-HIV-1 agents. Investigation on the CD4-Suradista binding mode through docking experiments.

Authors:  F Manetti; F Corelli; N Mongelli; A L Borgia; M Botta
Journal:  J Comput Aided Mol Des       Date:  2000-05       Impact factor: 3.686

3.  Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.

Authors:  R J Pither; C X Zhang; C Shiels; J Tarlton; S Finerty; A J Morgan
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

Review 4.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

5.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.

Authors:  J J De Jong; A De Ronde; W Keulen; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro.

Authors:  M Levi; M Sällberg; U Rudén; D Herlyn; H Maruyama; H Wigzell; J Marks; B Wahren
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

7.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

8.  Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites.

Authors:  A Pinter; W J Honnen; S A Tilley
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

9.  Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation.

Authors:  A C Andeweg; P Leeflang; A D Osterhaus; M L Bosch
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.

Authors:  F Kirchhoff; K Mori; R C Desrosiers
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.